Tumor Akkermansia muciniphila predicts clinical response to immune checkpoint inhibitors in non-small-cell lung cancer patients with low PD-L1 expression

IntroductionA prior retrospective analysis demonstrated that quantifying Programmed Cell Death Ligand 1 (PD-L1) expression using a phosphor-integrated dot (PID) score effectively predicted immune checkpoint inhibitor (ICI) efficacy in non-small-cell lung cancer (NSCLC) and other cancers. However, PD...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Takashi Shimizu, Ryotaro Ohkuma, Mayumi Homma, Shingo Nakayama, Yosuke Sasaki, Satoshi Muto, Katsuaki Ieguchi, Makoto Watanabe, Akashi Taguchi, Daisuke Takayanagi, Youichiro Wada, Atsushi Horiike, Yutaro Kubota, Hirotsugu Ariizumi, Masahiro Shimokawa, Yuya Hirasawa, Tomoyuki Ishiguro, Risako Suzuki, Nana Iriguchi, Emiko Mura, Kiyoshi Yoshimura, Mayumi Tsuji, Yuji Kiuchi, Hiroyuki Suzuki, Toshiko Yamochi
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2025-09-01
Edice:	Frontiers in Immunology
Témata:	tumor Akkermansia muciniphila immunohistochemistry PD-L1 immunecheckpoint inhibitors biomarker
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1528594/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!